De Novo Myelodysplastic Syndrome clinical trials at UCSF
1 in progress, 0 open to eligible people
Sorry, in progress, not accepting new patients
This phase Ib trial studies the side effects and best dose of ibrutinib when given together with azacitidine in treating patients with myelodysplastic syndrome that is likely to occur or spread (higher risk) and who were previously treated or untreated and unfit for or refused intense therapy. Ibrutinib and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
San Francisco, California and other locations